. 2021 Oct 18;22(20):11227. doi: 10.3390/ijms222011227

Table 2.

Composition and properties of nanoparticle delivery systems for anti-HBV genetic drugs.

Nanopreparation	Nanocarrier Composition	Ligand	Drugs	Method of Preparation	Particle Size (nm)	Encapsulation Efficiency (%)	Drug Loading (%)	Refs.
Ribozyme technology
Polymeric micelle	Chitosan oligosaccharide-grafted stearic acid	N/A	10–23 DNAzyme specific to e-gene ORF A¹⁸¹⁶UG	Self-aggregation	164.0 ± 2.1	N/A	N/A	[47]
	Chitosan oligosaccharide-SS-Octadecylamine	N/A	10–23 DNAzyme specific to e-gene ORF A¹⁸¹⁶UG	Self-aggregation	214.75 ± 3.43	96.48 ± 0.27	1.582 ± 0.004	[48]
	Chitosan oligosaccharide-SS-Octadecylamine	N/A	10–23 DNAzyme specific to s-gene ORF A¹⁵⁷UG	Self-aggregation	230.70 ± 6.16	96.45 ± 0.33	1.581 ± 0.005	[48]
RNA interference technology
Lipid nanoparticle	Cationic cholesteryl polyamine N1-cholesteryloxycarbonyl-3,7-diazanonane-1,9-diamine and the neutral colipid dioleoyl-l,r-phosphatidyl ethanolamine	Polyethylene glycol	siRNA	Film dispersion– sonication method	80–100	N/A	N/A	[49]
	Proprietary lipid nanoparticle platform (Arbutus Biopharma)	N/A	ARB-1740	Spontaneous vesicle formation	65–80	92–98	N/A	[50,51]
	Proprietary lipid nanoparticle platform (Arbutus Biopharma)	N/A	ARB-1467	Spontaneous vesicle formation	N/A	N/A	N/A	[52]
Polymeric nanoparticle	Poly(d,l-lactide-co-glycolide)-grafted chitosan (PLGA–CHS)	N/A	Plasmid DNA (pDNA)	Spontaneous emulsion diffusion method	59.43 ± 14	N/A	Nearly 100% at the ratio of 100:1 (PLGA–CHS NS to pDNA)	[53]
Polymeric nanoparticle	ARC-EX1 containing hepatocyte-targeted N-acetylgalactosamine-conjugated melittin-like peptide	N/A	ARC-520 along with a related ARC-521	N/A	N/A	N/A	N/A	[54,55]
Conjugate nanoparticle	N-acetylgalactosamine (GalNAc)–siRNA conjugates	N/A	ALN-HBV	N/A	N/A	N/A	N/A	[56,57,58]
Gene editing technology
Lipid-like nanoparticle	Tris(2-aminoethyl) benzene-1,3,5-tricarboxamide	N/A	CRISPR/Cas9	N/A	N/A	N/A	N/A	[59]
Lipid nanoparticle	Cationic lipid, phospholipid, cholesterol	Polyethylene glycol	CRISPR/Cas ribonucleoprotein	Mixer-equipped microfluidic device	<200	>80	N/A	[60]